Sales and Marketing

Showing 15 posts of 11528 posts found.

No-deal Brexit will “make the disintegration of the health service an ever more real prospect”, BMA warns

September 2, 2019 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMA, NHS, UK, brexit, pharma

As the UK hurtles towards a catastrophic and autocratic exit from the European Union, the British Medical Association (BMA) has …

AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk

September 2, 2019 Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma

AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …

Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients

September 2, 2019 Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …

Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial

September 2, 2019 Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma

Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …

Top Ten most popular articles on Pharmafile.com this week

August 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top 10

Happy Friday! It’s time for another rundown of the top 10 most popular articles with Pharmafile.com readers this week.10. NICE …

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

August 30, 2019 Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …

Using advanced digital capabilities to unlock hard-to-see HCPs access

August 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing digital pharma, pharma, veeva

Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their channel preferences and ensure they are getting …

Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder

August 28, 2019 Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris

Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …

FibroGen rocked by unexpected death of CEO Thomas B Neff

August 27, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, fibrogen, pharma

In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, its Chief Executive Officer and …

NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy

August 27, 2019 Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …

Japan approves Genmab’s Darzalex in newly diagnosed multiple myeloma

August 22, 2019 Sales and Marketing

Genmab has secured a new approval for its CD38 monoclonal antibody Darzalex (daratumumab), this time in Japan for the treatment …

NICE Chief Sir Andrew Dillon to step down in 2020

August 22, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK pharma, UK< pharma

It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible …

Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019 Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …
The Gateway to Local Adoption Series

Latest content